How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Publication|Articles|May 8, 2026
Pharmacy Practice in Focus: Health Systems
- May 2026
- Volume 15
- Issue 3
Muscle Mass Changes With Incretin-Based Therapies for Weight Loss
Fact checked by: Kirsty Mackay
This review examines evidence on changes in muscle mass with incretin-based therapies and focuses on current and emerging strategies to preserve and enhance skeletal muscle mass.
Advertisement
Advertisement
Purpose: This narrative review highlights the significance of lean body mass (LBM) and skeletal muscle mass (SMM), the health implications due to a reduction in LBM, how glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and GLP-1 RA/glucose-dependent insulinotropic polypeptides (GIPs) affect LBM, current strategies to preserve SMM, and other pipeline therapies for preserving SMM.
Related to this article
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Advertisement
Advertisement